首页> 美国卫生研究院文献>International Journal of Nanomedicine >Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake
【2h】

Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake

机译:用于口服多西紫杉醇的表面改性固体脂质纳米颗粒:增强肠道吸收和淋巴吸收

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Docetaxel is a potent anticancer drug, but development of an oral formulation has been hindered mainly due to its poor oral bioavailability. In this study, solid lipid nanoparticles (SLNs) surface-modified by Tween 80 or D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS 1000) were prepared and evaluated in terms of their feasibility as oral delivery systems for docetaxel. Tween 80-emulsified and TPGS 1000-emulsified tristearin-based lipidic nanoparticles were prepared by a solvent-diffusion method, and their particle size distribution, zeta potential, drug loading, and particle morphology were characterized. An in vitro release study showed a sustained-release profile of docetaxel from the SLNs compared with an intravenous docetaxel formulation (Taxotere®). Tween 80-emulsified SLNs showed enhanced intestinal absorption, lymphatic uptake, and relative oral bioavailability of docetaxel compared with Taxotere in rats. These results may be attributable to the absorption-enhancing effects of the tristearin nanoparticle. Moreover, compared with Tween 80-emulsified SLNs, the intestinal absorption and relative oral bioavailability of docetaxel in rats were further improved in TPGS 1000-emulsified SLNs, probably due to better inhibition of drug efflux by TPGS 1000, along with intestinal lymphatic uptake. Taken together, it is worth noting that these surface-modified SLNs may serve as efficient oral delivery systems for docetaxel.
机译:多西紫杉醇是一种有效的抗癌药,但是口服制剂的开发受到阻碍,主要是因为其口服生物利用度差。在这项研究中,制备了经吐温80或D-α-生育酚聚(乙二醇1000)琥珀酸酯(TPGS 1000)表面改性的固体脂质纳米颗粒(SLN),并就其作为多西紫杉醇口服给药系统的可行性进行了评估。通过溶剂扩散法制备了吐温80乳化和TPGS 1000乳化的三硬脂精基脂质纳米颗粒,并对它们的粒径分布,ζ电势,载药量和颗粒形态进行了表征。一项体外释放研究表明,与静脉内多西紫杉醇制剂(Taxotere®)相比,多西他赛从SLNs中的缓释特性。与紫杉醇相比,吐温80乳化的SLNs在大鼠中的肠吸收,淋巴吸收和多西紫杉醇的相对口服生物利用度提高。这些结果可能归因于三硬脂精纳米颗粒的吸收增强作用。此外,与Tween 80乳化的SLNs相比,多西他赛在大鼠中的肠道吸收和相对口服生物利用度在TPGS 1000乳化的SLNs中进一步提高,这可能是由于TPGS 1000更好地抑制了药物外排以及肠道淋巴吸收。综上所述,值得注意的是这些表面修饰的SLN可以作为多西紫杉醇的有效口服给药系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号